Refractory Asthma Stratification Programme (RASP) Bronchoscopy Study
NCT02883530 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 160
Last updated 2024-01-05
Summary
The Investigators hypothesise that asthma is not a single disease, but a syndrome resulting from several distinct underlying disease processes known as endotypes. There are approximately 30,000 genes in humans, and each gene is responsible for the production of a particular protein. Using a technique called "whole genome expression profiling" The Investigators have undertaken a small study looking at the activity of all 30,000 genes in the airway tissue of people with asthma. This work has identified 3 mutually exclusive distinct molecular patterns (endotypes) of severe asthma and has identified other potentially important molecular targets (manuscripts in preparation). In particular,the Investigators have found that 25-50% of patients have asthma associated with the activity of proteins called Th2 cytokines (Th2-high asthma). New treatments are in development that target this pathway. However, the Investigators do not know what is driving severe asthma in patients who do not express these Th2 cytokines. The aim of this study is to investigate in more detail the molecular mechanisms driving severe asthma in patients who do not express Th2 cytokines (Th2-low asthma), so that the Investigators can identify new targets for treatment in this group. To do this the Investigators will collect airway tissue via a telescope (bronchoscope), and analyse gene and protein expression in the tissue. The Investigators will then compare the molecular activity between patients with Th2-high and Th2-low asthma, and healthy control subjects (data obtained from a parallel study).
Conditions
- Persistent Asthma
Interventions
- PROCEDURE
-
Bronchoscopy
Flexible bronchoscopy will be performed under conscious sedation (with premedication using a mild sedative such as 1-2.5 mg IV midazolam) followed by use of topical anaesthesia (lidocaine spray) on the throat, vocal cords, and trachea in order to investigate the airways. The procedure allows sampling of the airway tissue to allow for laboratory analysis. Three brushings of a small area of the epithelial surface of an airway will be performed via a specialised channel of the bronchoscope with the use of a sterile cytology brush and up to eight 2-mm endobronchial biopsies.
Sponsors & Collaborators
-
Genentech, Inc.
collaborator INDUSTRY -
Queen's University, Belfast
collaborator OTHER - collaborator OTHER_GOV
-
University of Leicester
lead OTHER
Principal Investigators
-
Peter Bradding, MBBS · University of Leicester
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-09-26
- Primary Completion
- 2024-10-31
- Completion
- 2024-10-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
Genetic Risk Factors for Severe Asthma
NCT00090740 ·Status: COMPLETED
-
Center for Reducing Asthma Disparities - Harvard University/Boston Area Community Health Centers
NCT00281086 ·Status: COMPLETED
-
Identification of Asthma Phenotypes in Severe Asthmatics
NCT01623089 ·Status: RECRUITING
-
Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma
NCT05850494 ·Status: COMPLETED ·Phase: PHASE3
-
An Investigation of Tumor Necrosis Factor (TNF)-Alpha in Asthma Using Biopsy Explants and Primary Bronchial Epithelial Cell Cultures
NCT01161303 ·Status: COMPLETED
-
Assessment Of Disease Pathology And Key Therapeutic Targets In Severe Asthma
NCT00327197 ·Status: TERMINATED ·Phase: PHASE1
-
Comparison Of Molecular Targets In Mild To Severe Asthmatics And Healthy Subjects
NCT00331058 ·Status: TERMINATED ·Phase: PHASE1
-
Developing Asthma Interventions Using Community Based Research
NCT00728169 ·Status: COMPLETED
-
Develop and Implement Asthma Controlling Strategies (2)
NCT00005733 ·Status: COMPLETED
-
TNF Alpha in Refractory Asthma
NCT00276029 ·Status: COMPLETED ·Phase: NA
-
Exploring Asthma Exacerbations in Mepolizumab Treated Patients
NCT03324230 ·Status: COMPLETED
-
Low-dose Methotrexate for Change in Global Initiative for Asthma Step 5 Medications in Chronic Severe Asthma
NCT02124226 ·Status: UNKNOWN ·Phase: PHASE3
-
Severe Asthma Research Program - Wake Forest University
NCT01750411 ·Status: COMPLETED
-
Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma
NCT00587288 ·Status: COMPLETED ·Phase: PHASE2
-
Predicting the Response to Montelukast by Genetic Variation in Asthmatics
NCT00116324 ·Status: COMPLETED ·Phase: PHASE3
-
Individualizing Treatment for Asthma in Primary Care
NCT06272370 ·Status: COMPLETED ·Phase: PHASE4
-
Genetic Study of Familial Forms of Non-atopic Asthma
NCT02911220 ·Status: TERMINATED ·Phase: NA
-
Evaluation of the Control Level of Asthmatic Patients With Seasonal Increase of Respiratory Symptoms (High and/or Low)
NCT00882128 ·Status: COMPLETED
-
Glasgow Asthma and Allergy Study
NCT01618318 ·Status: COMPLETED
-
Cross-sectional Study for Identification and Description of Severe Asthma Patients
NCT02293265 ·Status: COMPLETED ·Phase: PHASE3
-
Prescribing Asthma Controller Medication According to Gene Status to Improve Quality of Life in Young People With Asthma
NCT02758873 ·Status: COMPLETED ·Phase: NA
-
Study of the Mechanisms of Asthma
NCT00595153 ·Status: COMPLETED ·Phase: PHASE1
-
Impact of Comorbidities, Some Biomarkers, Micro RNA in Childhood Asthma Phenotypes
NCT07230912 ·Status: NOT_YET_RECRUITING
-
Role of Inflammatory Mediators in AERD
NCT02824523 ·Status: COMPLETED
-
Community Based Study of Adult Onset Asthma
NCT00005544 ·Status: COMPLETED